USA stockpiling of remdesivir: How should the world respond?
Publication: Journal of Comparative Effectiveness Research
Abstract
The race to find an effective treatment for coronavirus disease 2019 (COVID-19) is still on, with only two treatment options currently authorized for emergency use and/or recommended for patients hospitalized with severe respiratory symptoms: low-dose dexamethasone and remdesivir. The USA decision to stockpile the latter has resulted in widespread condemnation and in similar action being taken by some other countries. In this commentary we discuss whether stockpiling remdesivir is justified in light of the currently available evidence.
Formats available
You can view the full content in the following formats:
References
1.
John Hopskins University of Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) (2020). https://coronavirus.jhu.edu/map.html
2.
Nussbaumer-Streit B, Mayr V, Dobrescu AI et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst. Rev. 4(4), CD013574 (2020).
3.
Onder G, Rezza G, Brusaferro S. Case–fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323(18), 1775–1776 (2020).
4.
Senanayake SL. Drug repurposing strategies for COVID-19. Future Drug Discov. 2(2), (2020) (Epub ahead of print).
5.
Rodrigo C, Fernando SD, Rajapakse S. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin. Microbiol. Infect. 26(8), 979–987 (2020).
6.
Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the treatment of Covid-19 – final report. N. Engl. J. Med. (2020) (Epub ahead of print).
7.
RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR et al. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N. Engl. J. Med. (2020) (Epub ahead of print).
8.
Shah HA, Baker T, Baker P et al. Dexamethasone for Severe and Critical COVID-19 Patients: Is It Suitable for Low-Resource Settings? (2020). www.cgdev.org/blog/dexamethasone-severe-and-critical-covid-19-patients-it-suitable-low-resource-settings
9.
Institute for Clinical and Economic Review. Whittington M, Campbell J. Alternative pricing models for remdesivir and other potential treatments for COVID-19 (2020). https://icer-review.org/wp-content/uploads/2020/06/ICER-COVID_Revised_Report_20200624.pdf
10.
Eastman RT, Roth JS, Brimacombe KR et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 6(5), 672–683 (2020).
11.
Brophy JM. US purchases world stocks of Remdesivir – why the rest of the world should be glad to be at the back of the queue (2020). https://blogs.bmj.com/bmj/2020/07/03/as-the-us-purchases-world-stocks-of-remdesivir-why-the-rest-of-the-world-should-be-glad-to-be-at-the-back-of-the-queue/
12.
Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395(10236), 1569–1578 (2020).
13.
Siemieniuk RA, Bartoszko JJ, Ge L et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 370, m2980 (2020).
14.
Gilead Sciences. Press Release: An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences (2020). www.gilead.com/news-and-press/press-room/press-releases/2020/6/an-open-letter-from-daniel-oday-chairman--ceo-gilead-sciences
15.
Boseley S. US secures world stock of key Covid-19 drug remdesivir. The Guardian (2020). www.theguardian.com/us-news/2020/jun/30/us-buys-up-world-stock-of-key-covid-19-drug
16.
WHO Solidarity Trial Consortium; Pan H, Peto R, Karim QA et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. This article is a preprint and has not been certified by peer review. medRxiv (2020). www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
17.
Leegwater E, Strik A, Wilms EB et al. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors. Clin. Infect. Dis. (2020) (Epub ahead of print).
18.
Gilead Sciences. Company statement: gilead sciences statement on the initiation of clinical testing of an inhaled solution of remdesivir for potential outpatient treatment of COVID-19 (2020). www.gilead.com/news-and-press/company-statements/gilead-sciences-statement-on-the-initiation-of-clinical-testing-of-an-inhaled-solution-of-remdesivir-for-potential-outpatient-treatment-of-covid19
19.
Staff Writer. Coronavirus treatment: cipla's remdesivir Cipremi launched in India, to cost ₹4,000 (2020). www.livemint.com/news/india/coronavirus-vaccine-cipla-launches-generic-version-of-remdesivir-in-india-11594223346722.html
Information & Authors
Information
Published In
Pages: 1243 - 1246
PubMed: 33274643
Copyright
© 2020 Future Medicine Ltd.
History
Received: 11 August 2020
Accepted: 19 October 2020
Published online: 4 December 2020
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
USA stockpiling of remdesivir: How should the world respond?. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0174
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Mukesh P. Ratnaparkhi, Avinash R. Tekade, Shailendra S. Salvankar, Sampada D. Dalvi, Gajanan M. Kulkarni, Mayur G. Markand, RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF REMDESIVIR IN IV FORMULATION, INDIAN DRUGS, 10.53879/id.62.06.15003, 62, 06, (45-49), (2025).
- Yu Huang, Shuiyang Xu, Xiang Zhao, Lei Wang, Qiaohong Lv, Suxian Wu, Qingqing Wu, Xuehai Zhang, Drug stockpiling behavior and its impact on anxiety among the general public in the early stage after the lifting of China’s Zero-COVID policy: results from a web-based survey, Frontiers in Pharmacology, 10.3389/fphar.2025.1524068, 16, (2025).
- Jamie Elvidge, Ashley Summerfield, Saskia Knies, Bertalan Németh, Zoltán Kaló, Wim Goettsch, Dalia M. Dawoud, Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations, International Journal of Technology Assessment in Health Care, 10.1017/S0266462323000223, 39, 1, (2023).